{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:37:13Z","timestamp":1792899433100,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.otc.2022.12.004","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:54:52Z","timestamp":1680828892000},"page":"285-293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Chemoradiation for Locoregionally Advanced Laryngeal Cancer"],"prefix":"10.1016","volume":"56","author":[{"given":"Andr\u00e9anne","family":"Leblanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toms Vengaloor","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Bouganim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.otc.2022.12.004_bib1","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2017.75.7385","article-title":"use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update","volume":"36","author":"Forastiere","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.otc.2022.12.004_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.otc.2022.12.004_bib3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00405-009-1028-2","article-title":"Current trends in initial management of laryngeal cancer: the declining use of open surgery","volume":"266","author":"Silver","year":"2009","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"3","key":"10.1016\/j.otc.2022.12.004_bib4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.2307\/3572025","article-title":"X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells","volume":"29","author":"Sinclair","year":"1966","journal-title":"Radiat Res"},{"issue":"1","key":"10.1016\/j.otc.2022.12.004_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.radonc.2011.05.036","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site","volume":"100","author":"Blanchard","year":"2011","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.otc.2022.12.004_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.otc.2022.12.004_bib7","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.otc.2022.12.004_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","article-title":"Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial","volume":"13","author":"Bourhis","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.otc.2022.12.004_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2004.08.021","article-title":"Final results of the 94\u201301 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma","volume":"22","author":"Denis","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.otc.2022.12.004_bib10","doi-asserted-by":"crossref","unstructured":"Sharma A., Kumar M., Bhasker S., et al., An open-label, noninferiority phase III RCT of weekly versus three weekly cisplatin and radical radiotherapy in locally advanced head and neck squamous cell carcinoma (ConCERT trial), Am Soc Clin Oncol, 40 (16) 2022, 6004.","DOI":"10.1200\/JCO.2022.40.16_suppl.6004"},{"issue":"1","key":"10.1016\/j.otc.2022.12.004_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0360-3016(00)00408-9","article-title":"The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck","volume":"47","author":"Suntharalingam","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.otc.2022.12.004_bib12","doi-asserted-by":"crossref","unstructured":"Patil V.M., Noronha V., Menon N.S., et al., Results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation, Am Soc Clin Oncol, 40 (17) 2022, LBA6003.","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA6003"},{"issue":"3","key":"10.1016\/j.otc.2022.12.004_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A\u00a0consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.otc.2022.12.004_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer","volume":"39","author":"Gebre-Medhin","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.otc.2022.12.004_bib15","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdx299","article-title":"induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II\u2013III trial","volume":"28","author":"Ghi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.otc.2022.12.004_bib16","doi-asserted-by":"crossref","unstructured":"Cohen E.E., Karrison T., Kocherginsky M., et al., DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F)(TPF) induction chemotherapy (IC) in patients with N2\/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN), Am Soc Clin Oncol, 30 (15),2012, 5500.","DOI":"10.1200\/jco.2012.30.15_suppl.5500"},{"issue":"7","key":"10.1016\/j.otc.2022.12.004_bib17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.otc.2022.12.004_bib18","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.otc.2022.12.004_bib19","doi-asserted-by":"crossref","first-page":"djv368","DOI":"10.1093\/jnci\/djv368","article-title":"Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil,\u00b1docetaxel for larynx preservation","volume":"108","author":"Janoray","year":"2016","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.otc.2022.12.004_bib20","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.otc.2022.12.004_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.otc.2022.12.004_bib22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/hed.20279","article-title":"Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (# 22931) and RTOG (# 9501)","volume":"27","author":"Bernier","year":"2005","journal-title":"Head Neck: J Sci Specialties Head Neck"},{"issue":"18","key":"10.1016\/j.otc.2022.12.004_bib23","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): A multicenter, noninferiority, phase II\/III randomized controlled trial","volume":"40","author":"Kiyota","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.otc.2022.12.004_bib24","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.otc.2022.12.004_bib25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.radonc.2007.12.021","article-title":"Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement","volume":"87","author":"Racadot","year":"2008","journal-title":"Radiother Oncol"},{"issue":"23","key":"10.1016\/j.otc.2022.12.004_bib26","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.2013.53.9163","article-title":"Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234","volume":"32","author":"Harari","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.otc.2022.12.004_bib27","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/j.ijrobp.2011.02.007","article-title":"Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis","volume":"81","author":"Sher","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.otc.2022.12.004_bib28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.radonc.2017.10.016","volume":"126","author":"Gr\u00e9goire","year":"2018","journal-title":"Radiother Oncol"},{"issue":"9","key":"10.1016\/j.otc.2022.12.004_bib29","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.otc.2022.12.004_bib30","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijrobp.2019.05.024","article-title":"Palliative Radiation Therapy for Head and Neck Cancers","volume":"105","author":"Grewal","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.otc.2022.12.004_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semradonc.2008.09.006","article-title":"Strategies for managing radiation-induced mucositis in head and neck cancer","volume":"19","author":"Rosenthal","year":"2009","journal-title":"Semin Radiat Oncol"},{"issue":"20","key":"10.1016\/j.otc.2022.12.004_bib32","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2010.32.4103","article-title":"Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial","volume":"29","author":"Henke","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.otc.2022.12.004_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.radonc.2007.07.009","article-title":"Dysphagia disorders in patients with cancer of the oropharynx are significantly affected by the radiation therapy dose to the superior and middle constrictor muscle: a dose-effect relationship","volume":"85","author":"Levendag","year":"2007","journal-title":"Radiother Oncol"},{"issue":"10212","key":"10.1016\/j.otc.2022.12.004_bib34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.otc.2022.12.004_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.oraloncology.2018.04.008","article-title":"Nivolumab vs investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression","volume":"81","author":"Ferris","year":"2018","journal-title":"Oral Oncol"},{"issue":"18","key":"10.1016\/j.otc.2022.12.004_bib36","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2217\/fon-2020-0184","article-title":"Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412","volume":"16","author":"Machiels","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.otc.2022.12.004_bib37","doi-asserted-by":"crossref","first-page":"viii397","DOI":"10.1093\/annonc\/mdy287.074","article-title":"IMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)","volume":"29","author":"Haddad","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.otc.2022.12.004_bib38","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MOO.0000000000000700","article-title":"Immunotherapy for head and neck cancer: From recurrent\/metastatic disease to (neo) adjuvant treatment in surgically resectable tumors","volume":"29","author":"Specenier","year":"2021","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.otc.2022.12.004_bib39","doi-asserted-by":"crossref","unstructured":"Clump D.A., Zandberg D.P., Skinner H.D., et al., A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate-or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN), Am Soc Clin Oncol, 40 (16),2022, 6007.","DOI":"10.1200\/JCO.2022.40.16_suppl.6007"},{"key":"10.1016\/j.otc.2022.12.004_bib40","doi-asserted-by":"crossref","unstructured":"Anderson C.M., Lee C.M., Kelley J.R., et al., ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC), Am Soc Clin Oncol, 40 (16), 2022, 6005.","DOI":"10.1016\/j.ijrobp.2022.07.518"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666522001864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666522001864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T21:45:17Z","timestamp":1729201517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666522001864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0030666522001864"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2022.12.004","relation":{},"ISSN":["0030-6665"],"issn-type":[{"value":"0030-6665","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoradiation for Locoregionally Advanced Laryngeal Cancer","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2022.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}